bloomberg forest laboratories inc said fiscal second quarter profit increased percent demand two biggest selling medicines net income quarter ended sept rose million cents share million cents year earlier reflecting sales lexapro antidepressant namenda alzheimer disease new york based forest said today statement profit beat analysts estimates sales jumped percent lexapro percent namenda two drugs accounted percent forest revenue quarter company said forest developing licensing new drugs reduce reliance lexapro namenda issue forest company sustain kind growth `` said timothy chiang analyst ftn midwest securities corp new york telephone interview today certainly company results better forecasts i still longer term view stock `` chiang rates forest shares neutral '' second quarter revenue forest increased percent million million year earlier sales lexapro climbed million namenda reached million forest federal court ruling july protecting lexapro started selling generic competition teva pharmaceutical industries ltd based petah tikva israel teva ca copy lexapro teva started selling generic form zoloft antidepressant made new york based pfizer inc drug industry analysts said generic might cut many new patients buy lexapro seen meaningful change prescribing patterns lexapro point `` goodman said forest licensed lexapro copenhagen based lundbeck acquired rights namenda merz group based frankfurt main germany namenda patents begin expiring forest may face generic competition drug early chiang said around company could dealing cliff falling cliff terms revenue base `` chiang said working hard put together late stage pipeline `` hey making another ssri enough market better yet try dual norepinephrine serotonin reuptake inhibitor market aggressively apparently worked cymbalta ask lilly seems like forest overly dependent two psych meds i would think given namenda modest benefits much growth many products offer benefits end widely used take neurontin example link bloomberg post